Disease · HP_0001263
Global developmental delay
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Global developmental delay. Diseases, record HP_0001263. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001263
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Global developmental delay
- Open Targets ID
- HP_0001263
- Other names
Delayed cognitive development, Delayed development, Delayed developmental milestones, Delayed intellectual development, Delayed milestones, Delayed psychomotor development, Developmental delay, Developmental delay in early childhood, Developmental delay, global, Developmental retardation, GDD, Lack of psychomotor development, Motor and developmental delay, Motormental retardation, Psychomotor delay, Psychomotor development deficiency, Psychomotor development failure, Psychomotor developmental delay, Retarded development, Retarded mental development, Retarded psychomotor development
- Highest stage of its drugs
- Phase 3, for 2 of its 5 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DARBEPOETIN ALFA | CHEMBL1201566 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GANCICLOVIR | CHEMBL182 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AUTOLOGOUS CORD BLOOD | CHEMBL4594461 | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| GLIMEPIRIDE | CHEMBL1481 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| GLYBURIDE | CHEMBL472 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets3
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ABCC8 | Sulfonylurea receptor 1, Kir6.2 | 2 | Sulfonylurea receptor 1, Kir6.2 blocker | Unknown | https://conductscience.org/library/genes/6833 | Drugs and targets |
| KCNJ11 | Sulfonylurea receptor 1, Kir6.2 | 2 | Sulfonylurea receptor 1, Kir6.2 blocker | Unknown | https://conductscience.org/library/genes/3767 | Drugs and targets |
| EPOR | Erythropoietin receptor | 1 | Erythropoietin receptor agonist | Phase 3 | https://conductscience.org/library/genes/2057 | Drugs and targets |
Trials3
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03169881 | Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants | Phase 3 | 650 | 2024-10-30 | Neurocognitive, Neuroprotective, Neonatal, Neurodevelopmental Impairment | DARBEPOETIN ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT00001100 | A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. | Phase 3 | 130 | Cytomegalovirus Infections | GANCICLOVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT05751525 | Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome | 21 | Neurodevelopmental Disorders, Intellectual Disability, Development Delay, ADHD, Autism Spectrum Disorder, Epilepsy | GLYBURIDE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Darbepoetin vs Placebo: deaths from any cause | 52 of 319 | 53 of 327 | 646 | NCT03169881 | Trial comparisons |
| Darbepoetin vs Placebo: serious adverse events | 85 of 316 | 92 of 325 | 641 | NCT03169881 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001263
GET https://conductscience.org/api/diseases/v1/HP_0001263/drugs